Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Phase 2 Completed 45 enrolled European Lung Cancer Working Party

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .

Timeline

Start: 2006-07
Primary completion: 2009-03
Completion: 2010-06

Publications

Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N, Paesmans M, Willems L, Sculier JP; European Lung Cancer Working Party (ELCWP). Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J. 2011 Jan;37(1):129-35. doi: 10.1183/09031936.00037310. Epub 2010 Jun 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	60 mg/m2	Intravenous
Subject	Valproate	Small molecule	20 mg/kg	Oral
Subject	Valproate	Small molecule	30 mg/kg	Oral

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Summary

Timeline

Publications

Drugs

Indications